Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Authors:

Abstract
Background: Epcoritamab, a subcutaneously administered (SC) bispecific CD3xCD20 antibody, has shown potent antitumor activity as a single agent and in combinati